Evidence map›Paper›PMID 37853350›Full record

ArticleClinical proteomics2023

Proteomic analyses reveal cystatin c is a promising biomarker for evaluation of systemic lupus erythematosus.

He Huang, Yukun Zhang, Lan Gui, Li Zhang, Minglong Cai, Yujun Sheng

Open access · goldAbstract read
In one paragraph

Article in Clinical proteomics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. [Classification of systemic lupus erythematosus resting-state functional magnetic resonance imaging data based on the end-to-end model].Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi · 2026
    Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

He Huang *Department of Dermatology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Yukun Zhang *Department of Dermatology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Lan GuiDepartment of Dermatology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Li ZhangDepartment of Rheumatology and Immunology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
Minglong CaiDepartment of Rheumatology and Immunology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China. aycaiml@163.com.
Yujun ShengDepartment of Dermatology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China. ahmusyj@163.com.
First Affiliated Hospital of Anhui Medical University · CNUniversity of Science and Technology of China · CNChina-Japan Friendship Hospital · CN

Funding

National Natural Science Foundation of China 81872527Outstanding Youth Project of Natural Science Foundation of Anhui Province 2208085Y25
6 · The paper itself

Abstract

backgroundSystemic lupus erythematosus (SLE) is an autoimmune disease with multiple organ involvement, especially the kidneys. However, the underlying mechanism remains unclear, and accurate biomarkers are still lacking. This study aimed to identify biomarkers to assess organ damage and disease activity in patients with SLE using quantitative proteomics.

methodsProteomic analysis was performed using mass spectrometry in 15 patients with SLE and 15 age-matched healthy controls. Proteomic profiles were compared in four main subtypes: SLE with proteinuria (SLE-PN), SLE without proteinuria (SLE-non-PN), SLE with anti-dsDNA positivity (SLE-DP), and SLE with anti-dsDNA negativity (SLE-non-DP). Gene ontology biological process analysis revealed differentially expressed protein networks. Cystatin C (CysC) levels were measured in 200 patients with SLE using an immunoturbidimetric assay. Clinical and laboratory data were collected to assess their correlation with serum CysC levels.

resultsProteomic analysis showed that upregulated proteins in both the SLE-PN and SLE-DP groups were mainly mapped to neutrophil activation networks. Moreover, CysC from neutrophil activation networks was upregulated in both the SLE-PN and SLE-DP groups. The associations of serum CysC level with proteinuria, anti-dsDNA positivity, lower complement C3 levels, and SLE disease activity index score in patients with SLE were further validated in a large independent cohort.

conclusionsNeutrophil activation is more prominent in SLE with proteinuria and anti-dsDNA positivity, and CysC is a promising marker for monitoring organ damage and disease activity in SLE.

Indexed as

BiomarkerCystatin CNeutrophil activationProteomicsSystemic lupus erythematosus

Identifiers

PMID37853350
PMCPMC10583312
OpenAlexW4387742221

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.